Acutaas Chemicals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹437 Cr +42.8% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
AC

Acutaas Chemicals Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Acutaas Chemicals Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹393Cr
+42.9% YoY
+28.4% QoQ
Net profit
₹106Cr
+135.6% YoY
+47.2% QoQ
Margin
38%
+13 pp YoY
+7 pp QoQ
Price₹3,169
Market cap₹26.9K Cr
P/E69.6

The short version

Acutaas Chemicals expects to grow revenue by more than 25% year-on-year for the next 3 to 5 years, maintaining strong double-digit growth (Page 16). Acutaas Chemicals aims for sustainable revenue growth above 25% annually for the next 3 to 5 years.

From Acutaas Chemicals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Acutaas Chemicals expects to grow revenue by more than 25% year-on-year for the next 3 to 5 years, maintaining strong double-digit growth (Page 16).
  • CDMO business is projected to cross INR 1,000 crores revenue by FY 2028, driven by multiple validated products and new contracts (Page 12, 17).
  • Battery chemical segment, especially products like vinyl carbonate (VC) and fluoroethylene carbonate (FEC), is in early stages with capacity and contracts in place; further products are planned for commercialization in mid-FY 2027 onwards (Page 8, 16).
  • Semiconductor chemical verticals (including Baba Fine Chem and Indichem JV) are expected to contribute meaningfully by 2028 with high EBITDA margins (Page 13, 16).

2 more points from Acutaas Chemicals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Acutaas Chemicals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Total capex for FY '26 is expected around INR 220 crores, slightly lower than earlier guidance of INR 250 crores due to spillover of the second phase of battery chemical and pilot plant capex.
  • Indichem joint venture (South Korea) investment: INR 130 crores invested so far out of total INR 200 crores announced; capex progressing as per plan; additional investment possible this quarter.
  • Second phase capex part of the INR 220 crore plan.
  • Ankleshwar plant utilization currently at 40%; growth till FY '28 expected with possible incremental pharma intermediate capex after 1.5 years based on market conditions.

2 more points from Acutaas Chemicals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Acutaas Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The company has good visibility of contracts for FY '27 and beyond, expecting fast scaling of its business.
  • For the additives business, there are fixed pricing contracts in place with variability linked to raw materials and currency.
  • The anticancer CDMO segment has long-term supply contracts, with projections extending through FY '28.
  • Four new CDMO products validated in the current financial year are expected to start contributing from FY '27.
  • Sampling and validation for additional CDMO products are underway, reinforcing a strong pipeline.
  • Battery chemical orders for VC and FEC products are already in hand with good revenue visibility for FY '27.
  • Two additional battery chemical products are expected to contribute to revenues starting mid-FY '27.

2 more points from Acutaas Chemicals Ltd's call on order book

Create a free account to keep reading this call

Acutaas Chemicals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Acutaas Chemicals Ltd Q3 FY26 results — key figures

Acutaas Chemicals Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue393275+42.9%306+28.4%
Operating profit (EBITDA)15169+118.8%95+58.9%
Operating margin38%25%+13 pp31%+7 pp
Profit before tax14563+130.2%96+51%
Net profit (PAT)10645+135.6%72+47.2%
EPS (₹)13.195.49+140.3%8.82+49.5%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹437 Cr, net profit ₹123 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Acutaas Chemicals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Acutaas Chemicals Ltd Q3 FY26 results?

Acutaas Chemicals expects to grow revenue by more than 25% year-on-year for the next 3 to 5 years, maintaining strong double-digit growth (Page 16). Acutaas Chemicals aims for sustainable revenue growth above 25% annually for the next 3 to 5 years.

What is Acutaas Chemicals Ltd share price analysis?

Acutaas Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 69.6 with a market cap of ₹26,877 Cr. Investors should review the full earnings analysis for detailed insights.

Is Acutaas Chemicals Ltd planning capital expenditure?

Total capex for FY '26 is expected around INR 220 crores, slightly lower than earlier guidance of INR 250 crores due to spillover of the second phase of battery chemical and pilot plant capex.

Keep Acutaas Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.